Inmune Bio, Inc. (INMB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Inmune Bio, Inc. (INMB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029512901ex10-1.htm THIRD AMENDED AND RESTATED INMUNE BIO INC. 2021 STOCK INCENTIVE PLAN Exhibit 10.1 THIRD AMENDED AND RESTATED INMUNE BIO INC. 2021 STOCK INCENTIVE PLAN 1 General 1.1 Purpose . The purposes of the Third Amended and Restated INmune Bio Inc. 2021 Stock
How this was made
The 30-second read
Why it matters
Based on the provided excerpt, the disclosure is primarily about updating the company’s equity compensation framework and governance items; it does not include clinical, financial, or deal terms that would directly reset valuation.
Market read
Traders may monitor for dilution/incentive changes, but the excerpt lacks any specific grant sizes, severance amounts, or operational catalysts.
What to watch
Traders should check the full 8-K for named individuals, effective dates, severance/termination terms, and any equity grant quantities that could affect dilution expectations.
Background
The filing is an SEC Form 8-K (Item 5.02 and 5.07) tied to director/officer changes and compensatory arrangements, with an exhibit containing the third amended and restated 2021 stock incentive plan.
Ticker impact
Inmune Bio filed an 8-K for director/officer departures and elections plus adoption of a third amended stock incentive plan exhibit.
Likely limited near-term impact unless the omitted 8-K details include material executive changes or large equity grants.
The provided text is largely boilerplate plan language; the only concrete, company-specific item is the filing of director/officer changes and the amended incentive plan exhibit.
Market effects
Minor read-through for biotech governance/compensation practices; no sector-wide regulatory or clinical signal in the excerpt.
None indicated.
None indicated.
Counterpoint
If the full 8-K includes specific executive departures or unusually large equity awards, the market reaction could be more than “low” despite the excerpt’s boilerplate.
Key entities
- issuerInmune Bio, Inc.
Subject of the 8-K; governance/officer changes and amended stock incentive plan exhibit.
